Call the Myeloma Infoline
0800 980 3332
If you're affected by myeloma
Myeloma news
Leading myeloma experts feature in BBC Radio 4 food programme
Leading experts from the myeloma community including Prof Jamie Cavenagh, St Bartholomew’s Hospital, London, Prof Brian Durie from the USA, and Eric Low, Chief Executive, Myeloma UK, have recently appeared on an episode of the “The Food Programme” on BBC Radio 4, to discuss the rol.....
Daratumumab receives breakthrough therapy designation in the US for myeloma
The United States Food and Drug Administration (FDA), the body responsible for licensing new drugs in the US, has granted ‘breakthrough therapy designation’ to a new potential anti-myeloma treatment called daratumumab. Breakthrough therapy designation is an accelerated review process for.....
Latest research news from the International Myeloma Workshop in Kyoto, Japan
The 14th International Myeloma Workshop (IMWG) has just drawn to a close in Kyoto, Japan, after an eventful five days of presentations, debates and discussions. The Workshop, held every two years, is focused entirely on myeloma, with experts from around the world convening at it. Many of the sessio.....
Myeloma UK welcomes new diagnostic test for myeloma
Myeloma UK welcomes the news that Serascience Limited has launched a new 10 minute diagnostic test for myeloma called Seralite™. The test measures free light chains, which can be markers of myeloma, in blood, urine or serum samples. If free light chains are detected the device shows a pink li.....
Aeternis Zentaris stops Phase III perifosine study
The Canadian pharmaceutical company Aeterna Zentaris has announced it has stopped the Phase III study of perifosine in myeloma following a recommendation by an independent data safety monitoring board (DSMB) that the drug was unlikely to benefit patients. Perifosine belongs to a new class of oral a.....
